# Robert Chang

> Robert Chang is the President and CEO of Myra Vision, a Campbell, California medtech company developing the Calibreye Titratable Glaucoma Therapy (TGT) Surgical System - an adjustable aqueous shunt designed to give glaucoma surgeons real-time, non-invasive control over intraocular pressure. With over 30 years of medical device executive experience spanning co-founding Ample Medical, leading MVRx, and serving as CTO at Sadra Medical (acquired by Boston Scientific), Chang brings a rare combination of hands-on engineering depth and serial CEO-level leadership to one of ophthalmology's most intractable surgical challenges. Myra Vision has raised $50M+ across seed, Series A, and a $25M Series B in 2023, and in early 2026 enrolled its first patient in the FDA-approved ADAPT pivotal study.

- **Role:** President & CEO at Myra Vision
- **Organizations:** Myra Vision, MVRx, Inc., Ample Medical, Sadra Medical, Boston Scientific, IsoStent, Devices for Vascular Intervention
- **Nationality:** American
- **Education:** BS, Mechanical Engineering, California Polytechnic State University, San Luis Obispo, SM, Mechanical Engineering, Massachusetts Institute of Technology
- **Known for:** Led Myra Vision through $50M+ total fundraising across seed, Series A ($17M), and Series B ($25M) rounds, Achieved first-in-human clinical use of Calibreye System in September 2023, Secured FDA IDE approval for the ADAPT pivotal study of Calibreye TGT in August 2025

## Career timeline

- **1991** — Associate Product Manager, Devices for Vascular Intervention
- **1995** — President & COO, IsoStent
- **2000** — Chief Operating Officer, Satiety
- **2002** — Co-Founder, President & CEO, Ample Medical
- **2009** — Executive Vice President & CTO, Sadra Medical (a Shifamed company)
- **2011** — Vice President, Boston Scientific Structural Heart (post-Sadra acquisition)
- **2013** — Co-Founder, President & CEO, MVRx, Inc.
- **2019** — President & CEO, Myra Vision (then Myra Medical)
- **2021** — MVRx, Inc. acquired in private transaction
- **2023-06** — Myra Vision closes $25M Series B led by Cormorant Asset Management
- **2023-09** — Myra Vision initiates first-in-human feasibility study of Calibreye System
- **2025-08** — FDA grants conditional IDE approval for ADAPT pivotal study
- **2026-01** — First patient enrolled in ADAPT clinical study of Calibreye TGT Surgical System

## Achievements

- Led Myra Vision through $50M+ total fundraising across seed, Series A ($17M), and Series B ($25M) rounds
- Achieved first-in-human clinical use of Calibreye System in September 2023
- Secured FDA IDE approval for the ADAPT pivotal study of Calibreye TGT in August 2025
- Enrolled first US patient in ADAPT clinical study in January 2026
- Successfully exited MVRx, Inc. via private acquisition in May 2021
- Served as EVP & CTO at Sadra Medical, which was acquired by Boston Scientific
- Co-founded Ample Medical, building from startup to exit
- Over 30 years of executive leadership across multiple successful medtech ventures

## Latest updates

- **2026-01** — First patient enrolled in the ADAPT US pivotal clinical study of the Calibreye TGT Surgical System
- **2025-08** — FDA granted conditional IDE approval for Myra Vision's ADAPT study
- **2023-09** — Myra Vision initiated first-in-human feasibility study of Calibreye System
- **2023-06** — Myra Vision closed $25M Series B financing led by Cormorant Asset Management

## Links

- Website: https://myravision.com
- LinkedIn: http://www.linkedin.com/in/robert-chang-1a58115
- YouTube: https://www.youtube.com/watch?v=yuurRcIPgHY

---

Profile page: https://yespress.io/robert-chang
Published by YesPress — https://yespress.io
Last updated: 2026-05-13